Advancing
clinical
outcomes and
improving
patient quality
of life

WE ARE NOVA EYE MEDICAL

With a legacy that spans more than 30 years in ophthalmology, Nova Eye Medical designs, develops, manufactures and markets a portfolio of proprietary glaucoma treatment technologies. Underpinning each of these technologies is our commitment to advance clinical outcomes and improve patient quality of life.

Learn More

Latest News

See all

iTrack™ Canaloplasty to be Featured in Numerous Scientific Presentations at the ASCRS 2023 Annual Meeting

Media Release iTrack

4 May, 2023

iTrack Advance First Surgeries and Sales in USA

ASX Announcement General iTrack Molteno3 AlphaRET

1 May, 2023

FDA Clears iTrack Advance for US Launch

ASX Announcement General iTrack Molteno3 AlphaRET

31 Mar, 2023

Latest Events

See all

Asia Pacific Association of Cataract and Refractive Surgeons (APACRS) 2023

Singapore

8 - 10 June, 2023

Women in Ophthalmology 2023

MARCO ISLAND, FLORIDA

24 - 27 Aug, 2023

European Society of Cataract and Refractive Surgery (ESCRS) 2023

Vienna, Austria

8 - 12 Sept, 2023

Based on the principles of angioplasty, iTrack^™ is an implant-free glaucoma surgery that combines 360-degree catheterization with viscodilation to mechanically remove blockages and to dilate Schlemm’s canal in order to remove outflow resistance — achieving excellent clinical outcomes while also preserving the viability of subsequent glaucoma treatments.

Visit the iTrack™ website
Glaucoma-iTrack.com

Visit the iTrack™ Advance website
iTrack-Advance.com

The Molteno3® Glaucoma Drainage Device is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe and complex glaucoma, with the added benefit of a simplified surgical procedure.

Visit the Molteno3 website
Glaucoma-Molteno.com

AlphaRET is a wholly owned subsidiary of Nova Eye Medical Limited, established to drive the commercial development of the 2RT™ project. 2RT™ is a breakthrough nano-pulse laser technology that stimulates the eye’s natural healing response to treat intermediate age-related macular degeneration (AMD), one of the world’s leading causes of blindness.

Visit Alpha-RET.com